AOD-9604 vs Semaglutide vs HGH Fragment: Fat Loss Peptide Showdown

AOD-9604: The Modified HGH Fat Fragment

Mechanism of Action

AOD-9604 (Advanced Obesity Drug) is a modified fragment of human growth hormone encompassing amino acids 177-191, with an additional tyrosine residue at the N-terminus. It was developed by Metabolic Pharmaceuticals (Melbourne, Australia) specifically to isolate the fat-metabolizing properties of HGH without the growth-promoting, diabetogenic, or IGF-1-stimulating effects.

The compound works through two simultaneous mechanisms:

1. Stimulation of lipolysis: AOD-9604 activates beta-3 adrenergic receptor pathways in adipose tissue, increasing cyclic AMP production and hormone-sensitive lipase activity. This directly mobilizes stored triglycerides from fat cells (Ng et al., 2000, Obesity Research).

2. Inhibition of lipogenesis: The peptide suppresses the activity of acetyl-CoA carboxylase and fatty acid synthase — the rate-limiting enzymes in de novo fat synthesis. This means even when caloric surplus occurs, the conversion of carbohydrates to stored fat is impaired.

Crucially, AOD-9604 does not affect blood glucose, does not stimulate IGF-1 production, and does not produce the anti-insulin effects of full-length HGH or its N-terminal fragments. This was confirmed in Phase IIb clinical trials where no changes in glucose tolerance, HbA1c, or insulin sensitivity were observed over 12 weeks of administration (Stier et al., 2003, Obesity Reviews).

Regulatory Status

AOD-9604 holds a unique regulatory position. In Australia, the Therapeutic Goods Administration (TGA) has approved it as a complementary medicine ingredient (listed, not registered — an important distinction). It's available in Australian compounding pharmacies as an oral or injectable preparation. In Canada and the United States, it remains a research peptide without therapeutic approval.

Dosing Protocol

• Standard research dose: 250-300 mcg/day subcutaneously
• Injection timing: Fasted state, typically morning upon waking
• Cycle length: 12-20 weeks (effects are gradual and cumulative)
• Reconstitution: Bacteriostatic water, stored refrigerated 2-8°C

Effectiveness Data

Clinical trials demonstrated:

• Average fat loss of 2.8 kg over 12 weeks versus placebo in obese subjects (without caloric restriction mandate)
• Preferential reduction of visceral adipose tissue
• No rebound weight gain in 12-week follow-up post-discontinuation
• Dose-dependent response with plateau at ~300 mcg/day

User-reported outcomes in research contexts typically show:

• 0.5-1.5 lbs fat loss per week when combined with modest caloric deficit
• Improved body composition without lean mass changes
• Effects become noticeable around weeks 4-6
• Best results in combination with regular exercise (compound appears to enhance exercise-induced lipolysis)

---

Semaglutide: The Appetite Annihilator

Mechanism of Action

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — structurally similar to native GLP-1 but engineered with a C-18 fatty acid chain that binds serum albumin, extending its half-life from 2 minutes to approximately 7 days. Originally developed for type 2 diabetes (Ozempic/Rybelsus), it received obesity indication approval as Wegovy at higher doses.

The fat loss mechanism is primarily central (brain-mediated):

1. Appetite suppression: GLP-1 receptors in the hypothalamus and brainstem regulate satiety. Semaglutide dramatically reduces hunger, food cravings, and reward-driven eating behavior (Blundell et al., 2017, Diabetes, Obesity and Metabolism).

2. Gastric slowing: Delayed gastric emptying increases meal-to-meal satiety and reduces caloric intake per eating occasion.

3. Metabolic effects: Improved insulin sensitivity, enhanced beta-cell function, and modest increases in energy expenditure at higher doses.

4. Food noise reduction: Perhaps the most impactful subjective effect — users report dramatic reduction in intrusive food thoughts, compulsive eating urges, and hedonic food-seeking behavior.

Regulatory Status

Semaglutide is a prescription medication in Canada, approved by Health Canada for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It requires physician prescription, is dispensed through licensed pharmacies, and is covered by some provincial drug plans for qualifying patients.

Dosing Protocol (Wegovy — weight management indication)

• Titration schedule: 0.25 mg weekly x 4 weeks → 0.5 mg x 4 weeks → 1.0 mg x 4 weeks → 1.7 mg x 4 weeks → 2.4 mg maintenance
• Administration: Once-weekly subcutaneous injection (abdomen, thigh, or upper arm)
• Duration: Indefinite (weight regain typically occurs upon discontinuation)

Effectiveness Data

The STEP clinical trial program (N > 4,500 across multiple trials) demonstrated:

• Mean weight loss of 14.9% of body weight over 68 weeks at 2.4 mg/week (Wilding et al., 2021, New England Journal of Medicine)
• 86% of participants lost ≥5% body weight
• 69% lost ≥10% body weight
• 50% lost ≥15% body weight
• Significant improvements in cardiovascular risk markers, blood pressure, lipid profiles, and inflammatory markers
• SELECT trial demonstrated 20% reduction in major adverse cardiovascular events (Lincoff et al., 2023, NEJM)

These are among the most impressive pharmaceutical weight loss outcomes ever documented outside of bariatric surgery.

[Internal Link: /semaglutide/]

---

HGH Fragment 176-191: The Original Fat Fragment

Mechanism of Action

HGH Fragment 176-191 is the exact C-terminal fragment of human growth hormone (amino acids 176-191). Unlike AOD-9604, which is a modified version of this sequence, HGH Frag 176-191 is the unmodified natural sequence.

Its mechanism is essentially identical to AOD-9604's core lipolytic pathway:

• Beta-oxidation of fatty acids
• Hormone-sensitive lipase activation
• Inhibition of lipogenesis
• No IGF-1 stimulation
• No glucose metabolism effects

The key difference from AOD-9604 is the absence of the tyrosine modification and the slightly different receptor binding affinity profile. Some researchers consider them functionally equivalent; others argue AOD-9604's modifications improve stability and bioavailability.

Dosing Protocol

• Standard research dose: 250-500 mcg/day subcutaneously (often split into 2 doses)
• Injection timing: Fasted state, minimum 30 minutes before food
• Morning dose: 250 mcg upon waking
• Evening dose (optional): 250 mcg before bed (fasted 2+ hours)
• Cycle length: 8-16 weeks

Effectiveness Data

Clinical data on the unmodified fragment is limited compared to AOD-9604, as the pharmaceutical development effort shifted to the AOD-9604 modification. However:

• Animal studies demonstrate comparable lipolytic activity to full-length HGH without growth or diabetogenic effects (Ng et al., 2000)
• User-reported results suggest 0.5-1 lb fat loss per week when combined with caloric deficit
• Effects are fasted-state dependent (insulin presence abolishes lipolytic activity)
• Requires strict food timing discipline for optimal results

[Internal Link: /hgh-fragment-176-191/]

---

Mechanism Comparison Table

---

Effectiveness Ranking: Context Matters

For Total Weight Loss (Maximum Scale Movement)

Winner: Semaglutide — No contest. A 15% body weight reduction average is 2-3x the magnitude achievable with peptide lipolytic agents. If absolute weight loss is the primary metric, semaglutide is categorically superior.

For Fat-Specific Loss (Preserving Lean Mass)

Winner: AOD-9604 / HGH Fragment — These compounds specifically mobilize adipose tissue without catabolic effects on muscle. Semaglutide's weight loss includes significant lean mass reduction (approximately 25-40% of total weight lost), which is problematic for individuals prioritizing body composition over scale weight (Wilding et al., 2021).

For Visceral Fat Reduction

Winner: Tie (AOD-9604 and Semaglutide) — Both demonstrate preferential visceral fat reduction in clinical data. HGH Fragment likely shares this property but has less clinical evidence to confirm.

For Metabolic Health Improvement

Winner: Semaglutide — Beyond weight loss, the cardiovascular risk reduction, glycemic improvement, and inflammatory marker reduction documented in SELECT and STEP trials put semaglutide in a different therapeutic category entirely.

For Athletes and Physique Competitors

Winner: AOD-9604 or HGH Fragment — Lean mass preservation, no appetite suppression (athletes need to eat), no GI disturbance, and no performance-impairing side effects make these the clear choice for active individuals managing body composition for competition.

---

Side Effect Comparison

AOD-9604 Side Effects

Common:

• Injection site redness/irritation (mild, transient)
• Very mild headache in first 1-2 weeks

Uncommon:

• Slight nausea if injected on a non-empty stomach
• Temporary hypoglycemia symptoms (rare, usually in individuals on concurrent insulin-sensitizing agents)

Serious: None documented in clinical trials or post-market surveillance

Semaglutide Side Effects

Very common (>20% of users):

• Nausea (44% in STEP trials, typically worst during titration)
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain

Common (5-20%):

• Headache
• Fatigue
• Dyspepsia
• Dizziness
• Injection site reactions

Uncommon but serious:

• Pancreatitis (0.2-0.3% in trials)
• Gallbladder disease/gallstones (accelerated by rapid weight loss)
• Gastroparesis (potentially persistent after discontinuation in some cases)
• Muscle loss (25-40% of weight lost is lean tissue)
• "Ozempic face" (facial volume loss from rapid fat reduction)
• Thyroid C-cell tumors (animal data; human risk uncertain, contraindicated in personal/family history of medullary thyroid carcinoma)

Discontinuation/rebound:

• 67% of weight is regained within 1 year of stopping semaglutide (Wilding et al., 2022, Diabetes, Obesity and Metabolism)

HGH Fragment 176-191 Side Effects

Common:

• Injection site irritation
• Mild drowsiness if taken before bed

Uncommon:

• Temporary headache during first week
• Hypoglycemia symptoms if combined with intense fasted exercise

Serious: None documented

---

Cost Comparison (Canadian Context)

AOD-9604

• Research peptide cost: $60-90 CAD per 5 mg vial
• Monthly cost at 300 mcg/day: ~$110-160 CAD
• 12-week protocol cost: ~$330-480 CAD
• No prescription required

Semaglutide (Wegovy)

• Retail pharmacy cost: $400-500 CAD per monthly pen (at maintenance dose)
• With private insurance: $0-100 CAD copay (coverage varies by plan)
• Without insurance: ~$5,000-6,000 CAD annually
• Requires physician prescription + ongoing monitoring
• Some provincial coverage for BMI ≥30 or ≥27 with comorbidities

HGH Fragment 176-191

• Research peptide cost: $40-70 CAD per 5 mg vial
• Monthly cost at 500 mcg/day: ~$130-200 CAD
• 12-week protocol cost: ~$390-600 CAD
• No prescription required

Cost-Per-Pound-Lost Analysis (Estimated)

On a per-pound basis, all three are surprisingly comparable. Semaglutide's higher absolute cost is offset by greater magnitude of loss. However, the lean mass loss with semaglutide means the cost-per-pound-of-fat (versus total weight) is higher than it appears.

---

Who Should Use Which?

Choose AOD-9604 If:

• You want fat-specific loss without muscle catabolism
• You're already lean (15-20% body fat) and want to get leaner
• You're an athlete who needs to maintain performance and appetite
• You prefer a gentle compound with virtually no systemic side effects
• You don't want prescription involvement
• You're patient with moderate, sustained results
• You can commit to daily fasted injections

Choose Semaglutide If:

• You have significant weight to lose (BMI 30+ or 27+ with comorbidities)
• Appetite/food noise is your primary obstacle
• You've failed dietary interventions repeatedly
• You want the cardiovascular and metabolic health benefits beyond weight loss
• You have access to a prescribing physician and budget for ongoing therapy
• You understand and accept the lean mass trade-off
• You're prepared for potential long-term or indefinite use

Choose HGH Fragment 176-191 If:

• You want a straightforward lipolytic peptide without modifications
• You're comfortable with twice-daily fasted injections
• You prefer the unmodified natural HGH sequence
• Budget is a moderate concern (slightly cheaper per vial than AOD-9604)
• You're stacking with other GH-axis peptides and want fat loss without IGF-1 interference

---

Stacking Considerations

AOD-9604 Stacks Well With:

• CJC-1295 / Ipamorelin (GH pulse for additional lipolysis without overlapping mechanism)
• L-carnitine injectable (enhanced fatty acid transport into mitochondria)
• Thyroid peptides (T3/T4 for metabolic rate support)

Semaglutide Stacks Cautiously With:

• Resistance training + high protein intake (mandatory to mitigate lean mass loss)
• Creatine (lean mass preservation support)
• Caution with other GI-active compounds
• BPC-157 (some use for GI side effect mitigation — evidence limited)

HGH Fragment 176-191 Stacks Well With:

• Same stacks as AOD-9604
• Can be combined with AOD-9604 (overlapping mechanism, some users report additive effect)
• Mod GRF 1-29 + GHRP stack (different mechanisms, complementary fat loss pathways)

[Internal Link: /ipamorelin/] [Internal Link: /bpc-157/]

---

Frequently Asked Questions

Can I use AOD-9604 and semaglutide together?

Mechanistically, there's no contraindication — they work through completely different pathways. AOD-9604 mobilizes fat peripherally while semaglutide reduces caloric intake centrally. Some practitioners combine them, reasoning that the peripheral lipolytic signal plus reduced caloric intake could improve the fat-to-lean loss ratio. However, this combination hasn't been studied formally, and the GI side effects of semaglutide may complicate the fasted-state requirement for AOD-9604 dosing.

Does AOD-9604 work without exercise or caloric deficit?

Clinical trial data shows modest fat loss even without mandated exercise or caloric restriction. However, practical outcomes improve substantially with even moderate caloric deficit (300-500 kcal/day) and regular exercise. Think of AOD-9604 as a force multiplier for your existing fat loss efforts rather than a standalone solution.

Why does semaglutide cause muscle loss but AOD-9604 doesn't?

Semaglutide creates a significant caloric deficit through appetite suppression — often 500-1,000+ kcal/day reduction. Any large caloric deficit causes lean mass loss unless specifically countered with resistance training and high protein intake. AOD-9604 and HGH Fragment don't suppress appetite or create caloric deficit; they directly mobilize stored fat for oxidation without catabolic signaling to muscle tissue.

Is HGH Fragment 176-191 just a cheaper version of AOD-9604?

Not exactly. HGH Fragment 176-191 is the unmodified natural sequence; AOD-9604 is that sequence with a tyrosine addition and slight structural modifications designed to improve stability and receptor affinity. Think of AOD-9604 as the "pharmaceutical development" version of the natural fragment. Some researchers prefer the unmodified version on principle; others prefer AOD-9604's slightly optimized pharmacology.

What happens when I stop each compound?

AOD-9604 / HGH Fragment: Fat loss ceases, but there's no rebound effect. Body fat stays at whatever level you achieved, assuming caloric balance is maintained. Semaglutide: Clinical data shows approximately two-thirds of lost weight is regained within one year of discontinuation, driven by the return of pre-treatment appetite and food-seeking behavior. This is semaglutide's most significant limitation — it appears to require indefinite use for sustained effect.

---

Conclusion

There is no single "best fat loss peptide." The optimal choice depends entirely on your starting point, your goals, and your constraints. Semaglutide delivers the most dramatic weight loss but requires prescription access, indefinite use, and acceptance of lean mass reduction. AOD-9604 and HGH Fragment 176-191 offer targeted fat mobilization with minimal side effects and no muscle catabolism, but require patience and daily discipline.

For most Canadian researchers exploring peptide-assisted fat loss without prescriber involvement, AOD-9604 represents the best-documented option with the most favorable safety and effectiveness profile. For those with access to medical supervision and significant weight to lose, semaglutide's clinical evidence is unmatched. And for those who prefer nature-identical compounds with proven lipolytic mechanisms, HGH Fragment 176-191 delivers the original fat-burning sequence of growth hormone in concentrated form.

[Internal Link: /aod-9604/] [Internal Link: /hgh-fragment-176-191/]

---

This article is for educational and informational purposes only. Compounds discussed are for research purposes or require medical prescription. Consult a qualified healthcare provider before beginning any peptide or pharmaceutical protocol.